All In Biotech

NDA 018058 · Curium

Gallium Citrate Ga 67

Gallium Citrate Ga-67 · Injection

Last checked: Nov 20, 2026Latest source record: Mar 19, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Feb 1, 1979

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

1 Phase 3, 0 recruiting

FAERS reports

4

4 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 13, 2025.

INDICATIONS AND USAGE Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 1, 1979 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • GALLIUM CITRATE GA 67 · GALLIUM CITRATE GA-67 2mCi/ML · INJECTABLE, INJECTION · Prescription · TE BS

Clinical trials

Interventional ClinicalTrials.gov studies with "Gallium Ga-67" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • erythema2
  • inflammation2
  • rash pruritic2
  • urticaria2
  • anaphylactic reaction1
  • blood pressure decreased1
  • cardiac arrest1
  • device related thrombosis1
  • electrocardiogram abnormal1
  • lung opacity1
  • off label use1
  • palpable purpura1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20211
20221
20231
20251

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Curium

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.